- Home
- WASH vs XERS Comparison
WASH vs XERS Comparison
Compare WASH & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WASH
- XERS
- Stock Information
- Founded
- WASH 1800
- XERS 2005
- Country
- WASH United States
- XERS United States
- Employees
- WASH N/A
- XERS N/A
- Industry
- WASH Major Banks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- WASH Finance
- XERS Health Care
- Exchange
- WASH Nasdaq
- XERS Nasdaq
- Market Cap
- WASH 647.4M
- XERS 526.3M
- IPO Year
- WASH N/A
- XERS 2018
- Fundamental
- Price
- WASH $30.86
- XERS $5.49
- Analyst Decision
- WASH Buy
- XERS Strong Buy
- Analyst Count
- WASH 2
- XERS 6
- Target Price
- WASH $35.00
- XERS $5.92
- AVG Volume (30 Days)
- WASH 183.8K
- XERS 4.3M
- Earning Date
- WASH 04-21-2025
- XERS 03-06-2025
- Dividend Yield
- WASH 7.26%
- XERS N/A
- EPS Growth
- WASH N/A
- XERS N/A
- EPS
- WASH N/A
- XERS N/A
- Revenue
- WASH $98,251,000.00
- XERS $203,070,000.00
- Revenue This Year
- WASH $60.13
- XERS $31.75
- Revenue Next Year
- WASH $9.09
- XERS $21.09
- P/E Ratio
- WASH N/A
- XERS N/A
- Revenue Growth
- WASH N/A
- XERS 23.89
- 52 Week Low
- WASH $24.11
- XERS $1.69
- 52 Week High
- WASH $40.59
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- WASH 45.71
- XERS 68.07
- Support Level
- WASH $30.74
- XERS $4.33
- Resistance Level
- WASH $32.22
- XERS $6.07
- Average True Range (ATR)
- WASH 0.75
- XERS 0.30
- MACD
- WASH 0.08
- XERS 0.01
- Stochastic Oscillator
- WASH 56.69
- XERS 66.67
About WASH Washington Trust Bancorp Inc.
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates. The bank generates a majority of its revenue from the Commercial Banking segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.